+关注
卢先森呀
暂无个人介绍
IP属地:浙江
18
关注
0
粉丝
0
主题
0
勋章
主贴
热门
卢先森呀
2025-03-21
利好!冲
德琪医药-B(06996)发布年度业绩,经调整年内亏损3.05亿元 同比减少42.95%
卢先森呀
2020-10-13
$先声药业(02096)$
乙组吗?
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3451601809603716","uuid":"3451601809603716","gmtCreate":1568815716103,"gmtModify":1568815716103,"name":"卢先森呀","pinyin":"lxsyluxiansenya","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":18,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖(非转发)","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.14","exceedPercentage":"93.20%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.03.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.09.28","exceedPercentage":"80.85%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"浙江","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":415934497288528,"gmtCreate":1742554815230,"gmtModify":1742561716450,"author":{"id":"3451601809603716","authorId":"3451601809603716","name":"卢先森呀","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3451601809603716","idStr":"3451601809603716"},"themes":[],"htmlText":"利好!冲","listText":"利好!冲","text":"利好!冲","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/415934497288528","repostId":"2521347546","repostType":2,"repost":{"id":"2521347546","kind":"news","pubTimestamp":1742546200,"share":"https://www.laohu8.com/m/news/2521347546?lang=zh_CN&edition=full","pubTime":"2025-03-21 16:36","market":"sh","language":"zh","title":"德琪医药-B(06996)发布年度业绩,经调整年内亏损3.05亿元 同比减少42.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2521347546","media":"智通财经","summary":"智通财经APP讯,德琪医药-B(06996)发布截至2024年12月31日止年度业绩,该集团取得收入人民币9195万元(单位下同),同比增加36.62%;研发开支2.59亿元,同比减少36.18%;年内亏损3.19亿元,同比减少45.07%;经调整年内亏损3.05亿元,同比减少42.95%;每股亏损0.51元。公告称,收入增长主要得益于中国内地的加速贡献,该地区的收入增长了27.4%,主要受销量大幅上升所驱动。尽管希维奥®(塞利尼索)于2023年12月获纳入国家医保目录(国家医保目录)后价格大幅下调,仍实现了强劲的销售表现。","content":"<html><body><p>智通财经APP讯,<a href=\"https://laohu8.com/S/06996\">德琪医药-B</a>(06996)发布截至2024年12月31日止年度业绩,该集团取得收入人民币9195万元(单位下同),同比增加36.62%;研发开支2.59亿元,同比减少36.18%;年内亏损3.19亿元,同比减少45.07%;经调整年内亏损3.05亿元,同比减少42.95%;每股亏损0.51元。</p><p>公告称,收入增长主要得益于中国内地的加速贡献,该地区的收入增长了27.4%,主要受销量大幅上升所驱动。尽管希维奥®(塞利尼索)于2023年12月获纳入国家医保目录(国家医保目录)后价格大幅下调,仍实现了强劲的销售表现。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>德琪医药-B(06996)发布年度业绩,经调整年内亏损3.05亿元 同比减少42.95%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n德琪医药-B(06996)发布年度业绩,经调整年内亏损3.05亿元 同比减少42.95%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-21 16:36 北京时间 <a href=http://www.zhitongcaijing.com/content/detail/1265400.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯,德琪医药-B(06996)发布截至2024年12月31日止年度业绩,该集团取得收入人民币9195万元(单位下同),同比增加36.62%;研发开支2.59亿元,同比减少36.18%;年内亏损3.19亿元,同比减少45.07%;经调整年内亏损3.05亿元,同比减少42.95%;每股亏损0.51元。公告称,收入增长主要得益于中国内地的加速贡献,该地区的收入增长了27.4%,主要受销量...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1265400.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1191":"制药","06996":"德琪医药-B","BK1583":"高瓴概念","BK1574":"生物医药B类股"},"source_url":"http://www.zhitongcaijing.com/content/detail/1265400.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2521347546","content_text":"智通财经APP讯,德琪医药-B(06996)发布截至2024年12月31日止年度业绩,该集团取得收入人民币9195万元(单位下同),同比增加36.62%;研发开支2.59亿元,同比减少36.18%;年内亏损3.19亿元,同比减少45.07%;经调整年内亏损3.05亿元,同比减少42.95%;每股亏损0.51元。公告称,收入增长主要得益于中国内地的加速贡献,该地区的收入增长了27.4%,主要受销量大幅上升所驱动。尽管希维奥®(塞利尼索)于2023年12月获纳入国家医保目录(国家医保目录)后价格大幅下调,仍实现了强劲的销售表现。","news_type":1,"symbols_score_info":{"06996":1}},"isVote":1,"tweetType":1,"viewCount":340,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":309359329,"gmtCreate":1602580134661,"gmtModify":1703827024788,"author":{"id":"3451601809603716","authorId":"3451601809603716","name":"卢先森呀","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3451601809603716","idStr":"3451601809603716"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/02096\">$先声药业(02096)$</a>乙组吗?","listText":"<a href=\"https://laohu8.com/S/02096\">$先声药业(02096)$</a>乙组吗?","text":"$先声药业(02096)$乙组吗?","images":[{"img":"https://static.tigerbbs.com/0b277f1238ee8621b4d34e8b0a81737a","width":"1176","height":"2400"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/309359329","isVote":1,"tweetType":1,"viewCount":4143,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3527667803686145","idStr":"3527667803686145"},"content":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心!如果您想创作优质文章,请查看老虎社区创作指引","text":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心!如果您想创作优质文章,请查看老虎社区创作指引","html":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心!如果您想创作优质文章,请查看老虎社区创作指引"}],"imageCount":1,"langContent":"CN","totalScore":0}],"hots":[{"id":309359329,"gmtCreate":1602580134661,"gmtModify":1703827024788,"author":{"id":"3451601809603716","authorId":"3451601809603716","name":"卢先森呀","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3451601809603716","idStr":"3451601809603716"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/02096\">$先声药业(02096)$</a>乙组吗?","listText":"<a href=\"https://laohu8.com/S/02096\">$先声药业(02096)$</a>乙组吗?","text":"$先声药业(02096)$乙组吗?","images":[{"img":"https://static.tigerbbs.com/0b277f1238ee8621b4d34e8b0a81737a","width":"1176","height":"2400"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/309359329","isVote":1,"tweetType":1,"viewCount":4143,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3527667803686145","idStr":"3527667803686145"},"content":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心!如果您想创作优质文章,请查看老虎社区创作指引","text":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心!如果您想创作优质文章,请查看老虎社区创作指引","html":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心!如果您想创作优质文章,请查看老虎社区创作指引"}],"imageCount":1,"langContent":"CN","totalScore":0},{"id":415934497288528,"gmtCreate":1742554815230,"gmtModify":1742561716450,"author":{"id":"3451601809603716","authorId":"3451601809603716","name":"卢先森呀","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3451601809603716","idStr":"3451601809603716"},"themes":[],"htmlText":"利好!冲","listText":"利好!冲","text":"利好!冲","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/415934497288528","repostId":"2521347546","repostType":2,"repost":{"id":"2521347546","kind":"news","pubTimestamp":1742546200,"share":"https://www.laohu8.com/m/news/2521347546?lang=zh_CN&edition=full","pubTime":"2025-03-21 16:36","market":"sh","language":"zh","title":"德琪医药-B(06996)发布年度业绩,经调整年内亏损3.05亿元 同比减少42.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2521347546","media":"智通财经","summary":"智通财经APP讯,德琪医药-B(06996)发布截至2024年12月31日止年度业绩,该集团取得收入人民币9195万元(单位下同),同比增加36.62%;研发开支2.59亿元,同比减少36.18%;年内亏损3.19亿元,同比减少45.07%;经调整年内亏损3.05亿元,同比减少42.95%;每股亏损0.51元。公告称,收入增长主要得益于中国内地的加速贡献,该地区的收入增长了27.4%,主要受销量大幅上升所驱动。尽管希维奥®(塞利尼索)于2023年12月获纳入国家医保目录(国家医保目录)后价格大幅下调,仍实现了强劲的销售表现。","content":"<html><body><p>智通财经APP讯,<a href=\"https://laohu8.com/S/06996\">德琪医药-B</a>(06996)发布截至2024年12月31日止年度业绩,该集团取得收入人民币9195万元(单位下同),同比增加36.62%;研发开支2.59亿元,同比减少36.18%;年内亏损3.19亿元,同比减少45.07%;经调整年内亏损3.05亿元,同比减少42.95%;每股亏损0.51元。</p><p>公告称,收入增长主要得益于中国内地的加速贡献,该地区的收入增长了27.4%,主要受销量大幅上升所驱动。尽管希维奥®(塞利尼索)于2023年12月获纳入国家医保目录(国家医保目录)后价格大幅下调,仍实现了强劲的销售表现。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>德琪医药-B(06996)发布年度业绩,经调整年内亏损3.05亿元 同比减少42.95%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n德琪医药-B(06996)发布年度业绩,经调整年内亏损3.05亿元 同比减少42.95%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-21 16:36 北京时间 <a href=http://www.zhitongcaijing.com/content/detail/1265400.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯,德琪医药-B(06996)发布截至2024年12月31日止年度业绩,该集团取得收入人民币9195万元(单位下同),同比增加36.62%;研发开支2.59亿元,同比减少36.18%;年内亏损3.19亿元,同比减少45.07%;经调整年内亏损3.05亿元,同比减少42.95%;每股亏损0.51元。公告称,收入增长主要得益于中国内地的加速贡献,该地区的收入增长了27.4%,主要受销量...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1265400.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1191":"制药","06996":"德琪医药-B","BK1583":"高瓴概念","BK1574":"生物医药B类股"},"source_url":"http://www.zhitongcaijing.com/content/detail/1265400.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2521347546","content_text":"智通财经APP讯,德琪医药-B(06996)发布截至2024年12月31日止年度业绩,该集团取得收入人民币9195万元(单位下同),同比增加36.62%;研发开支2.59亿元,同比减少36.18%;年内亏损3.19亿元,同比减少45.07%;经调整年内亏损3.05亿元,同比减少42.95%;每股亏损0.51元。公告称,收入增长主要得益于中国内地的加速贡献,该地区的收入增长了27.4%,主要受销量大幅上升所驱动。尽管希维奥®(塞利尼索)于2023年12月获纳入国家医保目录(国家医保目录)后价格大幅下调,仍实现了强劲的销售表现。","news_type":1,"symbols_score_info":{"06996":1}},"isVote":1,"tweetType":1,"viewCount":340,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}